Which drug is classified as an MAO-B inhibitor?

Selegiline is classified as a monoamine oxidase B (MAO-B) inhibitor, which is significant in the treatment of neurological disorders, particularly Parkinson's disease. By inhibiting the MAO-B enzyme, selegiline helps increase the levels of dopamine in the brain, enhancing dopaminergic activity, which is beneficial for individuals with Parkinson's disease who experience decreased dopamine production.

This mechanism of action has implications for the management of symptoms and may also provide neuroprotective effects. Selegiline is often used as an adjunct therapy to other dopaminergic medications, allowing for more effective control of motor symptoms associated with the disease.

Other options, while notable medications in their own right, serve different functions. Rasagiline, like selegiline, is also an MAO-B inhibitor but isn't the correct choice in this context. Donepezil is primarily used for Alzheimer's disease as an acetylcholinesterase inhibitor, and amitriptyline, an antidepressant, works differently and is not classified as an MAO-B inhibitor. Thus, the classification of selegiline as an MAO-B inhibitor aligns perfectly with its therapeutic application in managing neurological conditions.